The need for γ-retroviral (gRV) vectors with a self-inactivating (SIN) design for clinical application has prompted a shift in methodology of vector manufacturing from the traditional use of stable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback